secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0000885725-26-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Boston Scientific reports Q4 and full year 2025 results, announces acquisitions
-------------------------------------------------------------------------------

- Q4 2025 net sales $5.286B, up 15.9% reported; GAAP EPS $0.45, adjusted EPS $0.80.
- FY2025 net sales $20.074B, up 19.9%; GAAP net income $2.898B, adjusted EPS $3.06.
- Agreed to acquire Penumbra (PEN), a thrombectomy and neurovascular company.
- Agreed to acquire Valencia Technologies for its eCoin tibial nerve stimulation device.
- Completed acquisition of Nalu Medical for peripheral nerve stimulation system.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000006/0000885725-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000006/bsx-20260204.htm
  HTML page:      https://secwatch.observer/filing/0000885725-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer